Search…

East China Pharmaceuticals: Subsidiary HDM1002 Tablets Received Clinical Trial Approval from the US FDA.

23/07/2025

East China Pharmaceutical Announcement: Hangzhou Zhongmei East China Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received notification from the US Food and Drug Administration that the clinical trial application for the drug HDM1002 tablets submitted by Zhongmei East China has been approved by the FDA. HDM1002 tablets are used for weight management in overweight or obese individuals.

Latest

2 m ago

Hong Kong Technology Exploration (01137.HK) has exercised a total of 525,000 stock options granted under the 2012 stock option plan.

3 m ago

Indian oil refiners may need to look for new markets outside of Europe.

3 m ago

St. Bella (02508): Partial exercise of the over-allotment option, stabilization price period ends.

3 m ago

Spot platinum broke through the $1430.00 per ounce mark, with the latest reporting at $1431.60 per ounce, down 0.64% intraday.

4 m ago

According to the media, the bidding documents show that Indian oil refiner Nayara Energy has modified the terms of payment for spot sales of naphtha, requiring buyers to prepay or provide a letter of credit, with the goods scheduled to be shipped in mid-August. According to industry reports and LSEG ship tracking data, an oil tanker chartered by BP left the Vadinar port in India on Sunday without loading Nayara's ultra-low sulfur diesel. Ship brokers revealed to the media on Tuesday that the order was cancelled after the EU sanctions.

See all latest